Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy
Abstract
INTRODUCTION: Glypican-3 (GPC3) is a cell membrane-anchored heparan sulfate proteoglycan that has recently garnered attention as a cancer antigen owing to its high expression in numerous cancers, particularly hepatocellular carcinoma (HCC), and to limited expression in adult normal tissue. AREAS COVERED: Here, we propose the potential of GPC3 as a cancer antigen based on our experience with the GPC3 peptide vaccine against HCC, having developed a vaccine that progressed from preclinical studies to first-in-human clinical trials. In this review, we present a summary of the current status and future prospects of immunotherapies targeting GPC3 by focusing on clinical trials; peptide vaccines, mRNA vaccines, antibody therapy, and chimeric antigen receptor/T-cell receptor - T-cell therapy and discuss additional strategies for effectively eliminating HCC through immunotherapy. EXPERT OPINION: GPC3 is an ideal cancer antigen for HCC immunotherapy. In resectable HCC, immunotherapies that leverage physiological immune surveillance, immune checkpoint inhibitors, and GPC3-target cancer vaccines appear promising in preventing recurrence and could be considered as a prophylactic adjuvant therapy. However, in advanced HCC, clinical trials have not demonstrated sufficient anti-tumor efficacy, in contrast with preclinical studies. Reverse translation, bedside-to-bench research, is crucial to identify the factors that have hindered GPC3 target immunotherapies.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699 · see citing works
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · see citing works
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064 · see citing works
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470 · see citing works
Global burden of primary liver cancer in 2020 and predictions to 2040
Rumgay, H., Arnold, M., Ferlay, J., Lesi, O., Cabasag, C. J., Vignat, J., Laversanne, M., McGlynn, K. A., & Soerjomataram, I. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.021 · Cited by 2,197 · see citing works
Bruix, J., Takayama, T., Mazzaferro, V., Chau, G.-Y., Yang, J., Kudo, M., Cai, J., Poon, R. T., Han, K.-H., Tak, W. Y., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00198-9 · Cited by 1,120 · see citing works
Harding, J. J., Nandakumar, S., Armenia, J., Khalil, D. N., Albano, M., Ly, M., Shia, J., Hechtman, J. F., Kundra, R., El Dika, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2293 · Cited by 602 · see citing works
Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker
Nakatsura, T., Yoshitake, Y., Senju, S., Monji, M., Komori, H., Motomura, Y., Hosaka, S., Beppu, T., Ishiko, T., Kamohara, H., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00908-2 · Cited by 430 · see citing works
Self-citationShi, D., Shi, Y., Kaseb, A. O., Qi, X., Zhang, Y., Chi, J., Lü, Q., Gao, H., Jiang, H., Wang, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3259 · Cited by 388 · see citing works
Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy
Chong, E. A., Ruella, M., & Schuster, S. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2030164 · Cited by 340 · see citing works
Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., Kong, J., Wang, H., Yang, S., Gu, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1170 · Cited by 313 · see citing works
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin
Pang, N., Shi, J., Qin, L., Chen, A., Tang, Y., Yang, H., Huang, Y., Wu, Q., Li, X., He, B., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01128-9 · Cited by 303 · see citing works
Sawada, Y., Yoshikawa, T., Nobuoka, D., Shirakawa, H., Kuronuma, T., Motomura, Y., Mizuno, S., Ishii, H., Nakachi, K., Konishi, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3044 · Cited by 302 · see citing works
Self-citationInterleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
Steffin, D., Ghatwai, N., Montalbano, A., Rathi, P., Courtney, A. N., Arnett, A., Fleurence, J., Sweidan, R., Wang, T., Zhang, H., et al. (2024) · Nature · doi:10.1038/s41586-024-08261-8 · Cited by 300 · see citing works
Batra, S. A., Rathi, P., Guo, L., Courtney, A. N., Fleurence, J., Balzeau, J. C., Shaik, R. S., Nguyen, T. P., Wu, M., Bulsara, S., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0293 · Cited by 269 · see citing works
Yarchoan, M. M., Gane, E. J., Marron, T. U., Perales-Linares, R. F., Yan, J., Cooch, N. S., Shu, D. H., Fertig, E. J., Kagohara, L. T., Bartha, G. T., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02894-y · Cited by 267 · see citing works
Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy
Jiang, H., Hegde, S., & DeNardo, D. G. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2003-1 · Cited by 243 · see citing works
(1997) · PubMed · Cited by 239 · see citing works
Jiang, Z., Jiang, X., Chen, S., Lai, Y., Wei, X., Li, B., Lin, S., Wang, S., Wu, Q., Liang, Q., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00690 · Cited by 207 · see citing works
Guo, X., Jiang, H., Shi, B., Zhou, M., Zhang, H., Shi, Z., Du, G., Luo, H., Wu, X., Wang, Y., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01118 · Cited by 206 · see citing works
Yu, M., Luo, H., Fan, M., Wu, X., Shi, B., Di, S., Liu, Y., Pan, Z., Jiang, H., & Li, Z. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.012 · Cited by 188 · see citing works
Sawada, Y., Yoshikawa, T., Ofuji, K., Yoshimura, M., Tsuchiya, N., Takahashi, M., Nobuoka, D., Gotohda, N., Takahashi, S., Kato, Y., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1129483 · Cited by 178 · see citing works
Self-citationKomori, H., Nakatsura, T., Senju, S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2267 · Cited by 174 · see citing works
Self-citationAnti–Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver Cancer
Ishiguro, T., Sugimoto, M., Kinoshita, Y., Miyazaki, Y., Nakano, K., Tsunoda, H., Sugo, I., Ohizumi, I., Aburatani, H., Hamakubo, T., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1973 · Cited by 168 · see citing works
Gao, W., Tang, Z., Zhang, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms7536 · Cited by 156 · see citing works
Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects
Liu, Z., Liu, X., Liang, J., Liu, Y., Hou, X., Zhang, M., Li, Y., & Jiang, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.765101 · Cited by 151 · see citing works
Liu, Y., Di, S., Shi, B., Zhang, H., Wang, Y., Wu, X., Luo, H., Wang, H., Li, Z., & Jiang, H. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800033 · Cited by 145 · see citing works
Abou-Alfa, G. K., Puig, O., Daniele, B., Kudo, M., Merle, P., Park, J.-W., Ross, P., Peron, J.-M., Ebert, O., Chan, S., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.004 · Cited by 137 · see citing works
Next-Generation Cancer Immunotherapy Targeting Glypican-3
Shimizu, Y., Suzuki, T., Yoshikawa, T., Endo, I., & Nakatsura, T. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00248 · Cited by 136 · see citing works
Self-citationCai, Z., Su, X., Qiu, L., Li, Z., Li, X., Dong, X., Wei, F., Zhou, Y., Luo, L., Chen, G., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01467-8 · Cited by 123 · see citing works
Ueda, T., Kumagai, A., Iriguchi, S., Yasui, Y., Miyasaka, T., Nakagoshi, K., Nakane, K., Saito, K., Takahashi, M., Sasaki, A., et al. (2020) · Cancer Science · doi:10.1111/cas.14374 · Cited by 118 · see citing works
Self-citationShed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma
Sun, L., Gao, F., Gao, Z., Ao, L., Li, N., Ma, S., Jia, M., Li, N., Lu, P., Sun, B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001875 · Cited by 118 · see citing works
Tada, F., Abe, M., Hirooka, M., Ikeda, Y., Hiasa, Y., Lee, Y., Jung, N.-C., LEE, W.-B., Lee, H., Bae, Y., et al. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1626 · Cited by 117 · see citing works
Meng, F., Zhao, J., Tan, A. T., Hu, W., Wang, S., Jin, J., Wu, J., Li, Y., Shi, L., Fu, J., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10250-2 · Cited by 116 · see citing works
Li, T., Yang, J., Liu, W., Tang, X., Chen, J., Zhao, D., Wang, M., Xu, F., Lu, Y., Liu, B., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.051 · Cited by 115 · see citing works
Glypican‐3 antibodies: A new therapeutic target for liver cancer
Feng, M., & Ho, M. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.10.002 · Cited by 114 · see citing works
Lee, J., Lee, Y., Lee, M., Heo, M. K., Song, J., Kim, K., Lee, H., Yi, N., Lee, K., Suh, K., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.430 · Cited by 103 · see citing works
Chen, C., Li, K., Jiang, H., Song, F., Gao, H., Pan, X., Shi, B., Bi, Y., Wang, H., Wang, H., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1949-8 · Cited by 102 · see citing works
Identification of α‐fetoprotein‐specific T‐cell receptors for hepatocellular carcinoma immunotherapy
Zhu, W., Peng, Y., Wang, L., et al. (2018) · Hepatology · doi:10.1002/hep.29844 · Cited by 102 · see citing works
Nakatsura, T., Komori, H., Kubo, T., Yoshitake, Y., Senju, S., Katagiri, T., Furukawa, Y., Ogawa, M., Nakamura, Y., & Nishimura, Y. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1177 · Cited by 97 · see citing works
Self-citationNagano, H., Miyamoto, A., Wada, H., Ota, H., Marubashi, S., Takeda, Y., Dono, K., Umeshita, K., Sakon, M., & Monden, M. (2007) · Cancer · doi:10.1002/cncr.23033 · Cited by 94 · see citing works
Zhai, B., Shi, D., Gao, H., Qi, X., Jiang, H., Zhang, Y., Chi, J., Ruan, H., Wang, H., Ru, Q. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3049 · Cited by 84 · see citing works
Chen, H., Li, Z., Qiu, L., Dong, X., Chen, G., Shi, Y., Cai, L., Liu, W., Ye, H., Zhou, Y., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004389 · Cited by 83 · see citing works
The history of liver surgery: Achievements over the past 50 years
Kokudo, N., Takemura, N., Ito, K., & Mihara, F. (2020) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12322 · Cited by 83 · see citing works
Fu, Q., Zheng, Y., Fang, W. J., Zhao, Q. D., Zhao, P., Liu, L., Zhai, Y., Tong, Z., Zhang, H., Lin, M., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102175 · Cited by 83 · see citing works
Huang, Y., Zeng, J., Liu, T., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s253565 · Cited by 82 · see citing works
Sawada, Y., Yoshikawa, T., Shimomura, M., Iwama, T., Endo, I., & Nakatsura, T. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2737 · Cited by 78 · see citing works
Self-citationSystematic Review of Available CAR-T Cell Trials around the World
Barros, L. R. C., Couto, S. C. F., Santurio, D. S., Paixão, E. A., Cardoso, F. C., da Silva, V. J., Klinger, P. H. D. S., Ribeiro, P. D. A. C., Rós, F. A., de Oliveira, T. G. M., et al. (2022) · Cancers · doi:10.3390/cancers14112667 · Cited by 76 · see citing works
Gao, W., Kim, H., & Ho, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137664 · Cited by 74 · see citing works
Ikeda, M., Ohkawa, S., Okusaka, T., et al. (2014) · Cancer Science · doi:10.1111/cas.12368 · Cited by 73 · see citing works
Fleming, B. D., Urban, D. J., Hall, M. D., Longerich, T., Greten, T. F., Pastan, I. H., & Ho, M. (2019) · Hepatology · doi:10.1002/hep.30949 · Cited by 64 · see citing works
Tsuchiya, N., Hosono, A., Yoshikawa, T., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1377872 · Cited by 57 · see citing works
Zhang, Q., Fu, Q., Cao, W., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.2024.42.16_suppl.4019 · Cited by 57 · see citing works
Lu, L., Xiao, S.-X., Lin, Z., Bai, J. J., Li, W., Song, Z., Zhou, Y., Lu, B., & Wu, W. (2023) · Cell Biology and Toxicology · doi:10.1007/s10565-023-09821-w · Cited by 56 · see citing works
Shiraiwa, H., Narita, A., Kamata‐Sakurai, M., Ishiguro, T., Sano, Y., Hironiwa, N., Tsushima, T., Segawa, H., Tsunenari, T., Ikeda, Y., et al. (2018) · Methods · doi:10.1016/j.ymeth.2018.10.005 · Cited by 55 · see citing works
Atezolizumab plus Bevacizumab — A Landmark in Liver Cancer
Kelley, R. K. (2020) · New England Journal of Medicine · doi:10.1056/nejme2004851 · Cited by 53 · see citing works
Liu, X., Gao, F., Jiang, L., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02462-1 · Cited by 52 · see citing works
Chen, K., Wu, Z., Zhao, H., Wang, Y., Ge, Y., Wang, D., Li, Z., An, C., Liu, Y., Wang, F., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0210 · Cited by 49 · see citing works
Luo, H., Wu, X., Sun, R., Su, J., Wang, Y., Dong, Y., Shi, B., Sun, Y., Jiang, H., & Li, Z. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01448 · Cited by 48 · see citing works
Bispecific GPC3/PD‑1 CAR‑T cells for the treatment of HCC
Li, D., Qin, J., Zhou, T. Y., et al. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5501 · Cited by 48 · see citing works
Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy
Wang, C., Gao, W., Feng, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10592 · Cited by 47 · see citing works
Yang, H., Sun, L., Guan, A., Yin, H., Liu, M., Mao, X., Xu, H. C., Zhao, H., Lü, X., Sang, X., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02711-8 · Cited by 45 · see citing works
Matsui, H., Hazama, S., Nakajima, M., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02737-y · Cited by 41 · see citing works
Taniguchi, M., Mizuno, S., Yoshikawa, T., et al. (2020) · Cancer Science · doi:10.1111/cas.14497 · Cited by 40 · see citing works
Cao, G., Zhang, G., Liu, M., Liu, J., Wang, Q., Zhu, L., & Wan, X. (2022) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2022.101324 · Cited by 38 · see citing works
Sayem, M. A., Tomita, Y., Yuno, A., Hirayama, M., Irie, A., Tsukamoto, H., Senju, S., Yuba, E., Yoshikawa, T., Kono, K., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1062209 · Cited by 36 · see citing works
Self-citationZhao, R., Cheng, L., Jiang, Z., Wei, X., Li, B., Wu, Q., Wang, S., Lin, S., Long, Y., Zhang, X., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1509173 · Cited by 36 · see citing works
Hickman, T. L., Choi, E., Whiteman, K. R., Muralidharan, S., Pai, T., Johnson, T., Parikh, A. B., Friedman, T., Gilbert, M., Shen, B., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266980 · Cited by 35 · see citing works
Neoantigens as potential vaccines in hepatocellular carcinoma
Repáraz, D., Ruiz, M., Llópiz, D., Silva, L., Vercher, E., Aparicio, B., Egea, J., Tamayo, I., Hervás‐Stubbs, S., García-Balduz, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003978 · Cited by 34 · see citing works
Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances
Charneau, J., Suzuki, T., Shimomura, M., Fujinami, N., & Nakatsura, T. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s291558 · Cited by 33 · see citing works
Self-citationLuo, X., Cui, H., Cai, L., Zhu, W., Yang, W.-C., Patrick, M., Zhu, S., Huang, J., Yao, X., Yao, Y., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00623 · Cited by 32 · see citing works
Xiong, X., Xi, J., Liu, Q., et al. (2020) · Liver International · doi:10.1111/liv.14771 · Cited by 31 · see citing works
Safety and efficacy of blinatumomab: a real world data
Apel, A., Ofran, Y., Wolach, O., Shimony, S. O., Ram, R., Levi, I., Zektser, M., & Koren‐Michowitz, M. (2020) · Annals of Hematology · doi:10.1007/s00277-019-03854-0 · Cited by 30 · see citing works
Liu, D., Luo, Y., Chen, L., et al. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0207 · Cited by 30 · see citing works
A glypican-3-derived peptide vaccine against hepatocellular carcinoma
Sawada, Y., Sakai, M., Yoshikawa, T., et al. (2012) · OncoImmunology · doi:10.4161/onci.21351 · Cited by 30 · see citing works
Hu, W., Huang, X., Huang, X., Chen, W., Hao, L.-D., & Chen, Z. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109333 · Cited by 28 · see citing works
Sun, Y., Dong, Y., Sun, R., Liu, Y., Wang, Y., Luo, H., Shi, B., Jiang, H., & Li, Z. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.04.003 · Cited by 27 · see citing works
Derivation and Preclinical Characterization of CYT-303, a Novel NKp46-NK Cell Engager Targeting GPC3
Arulanandam, A., Lin, L., Chang, H., Cérutti, M., Choblet, S., Gao, P., Rath, A. V., Bensussan, A., Kadouche, J., Teper, D., et al. (2023) · Cells · doi:10.3390/cells12070996 · Cited by 27 · see citing works
Shimizu, Y., Mizuno, S., Fujinami, N., et al. (2019) · Cancer Science · doi:10.1111/cas.14251 · Cited by 26 · see citing works
Ikeda, M., Okusaka, T., Ohno, I., et al. (2021) · Immunotherapy · doi:10.2217/imt-2020-0278 · Cited by 25 · see citing works
Nakajima, M., Hazama, S., Tamada, K., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02518-7 · Cited by 23 · see citing works
Li, S., Zhao, R., Zheng, D., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.06.003 · Cited by 22 · see citing works
Wang, H., Wang, X., Ye, X., Ju, Y., Cao, N., Wang, S., & Cai, J. (2022) · BMC Cancer · doi:10.1186/s12885-022-09861-1 · Cited by 21 · see citing works
Nakajima, M., Hazama, S., Tokumitsu, Y., Shindo, Y., Matsui, H., Matsukuma, S., Nakagami, Y., Tamada, K., Udaka, K., Sakamoto, M., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13900 · Cited by 15 · see citing works
Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment
Han, R., Wang, Y., & Lu, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010059 · Cited by 15 · see citing works
Li, K., Qian, S., Huang, M., Chen, M., Peng, L., Liu, J., Xu, W., & Xu, J. (2021) · Europe PMC (PubMed Central) · Cited by 15 · see citing works
IL-2/GM-CSF enhances CXCR3 expression in CAR-T cells via the PI3K/AKT and ERK1/2 pathways
Liu, L., Cheng, Y. H., Zhang, F., Chen, J., Tian, P., Shi, W., Fei, Z., Yang, M., Zhou, M., & Liu, B. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04509-w · Cited by 14 · see citing works
Chen, K., Wu, Z., Zang, M., et al. (2018) · Europe PMC (PubMed Central) · Cited by 14 · see citing works
Okamura, Y., Sugiura, T., Ito, T., et al. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12451 · Cited by 13 · see citing works
Komatsu, S.-I., Kayukawa, Y., Miyazaki, Y., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16564-x · Cited by 12 · see citing works
Nakajima, M., Kobayashi, S., Wada, H., Tomokuni, A., Takahashi, H., Noda, T., Matsui, H., Matsukuma, S., Kanekiyo, S., Shindo, Y., et al. (2020) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12377 · Cited by 12 · see citing works
Li, X., Zhou, J., Zhang, W., You, W., Wang, J., Zhou, L., Liu, L., Chen, W., & Li, H. (2022) · Cancers · doi:10.3390/cancers14225674 · Cited by 11 · see citing works
Dash, C. P., Sonowal, D., Dhaka, P., Yadav, R., Chettri, D., Satapathy, B. P., Sheoran, P., Uttam, V., Jain, M., & Jain, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1390498 · Cited by 9 · see citing works
Zheng, Y., Lu, Z., Ding, J., et al. (2022) · Cancers · doi:10.3390/cancers14184512 · Cited by 9 · see citing works
Qin, L., Wang, J., Cheng, F., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03569-2 · Cited by 8 · see citing works
Jin, X., Liu, X. K., Zhou, Z., Ding, Y., Wu, Y., Qiu, J., & Shen, C. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03096-y · Cited by 6 · see citing works
Zeng, J., Liu, Y., Huang, F., et al. (2017) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/j.apjtm.2017.10.013 · Cited by 5 · see citing works
Huang, W.-L., Liu, Y., Hu, Y., et al. (2020) · PubMed · doi:10.13345/j.cjb.200106 · Cited by 4 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- 10.21203/rs.3.rs-4103623/v1 · DOI
Cited by
Still being checked.
- Authors
- Couzinet, A., Suzuki, T., & Nakatsura, T.
- Affiliations
- National Cancer Center Exploratory Oncology Research & Clinical Trial Center (JP)
- Corresponding author
- Nakatsura, Tetsuya
- ORCID
- Suzuki, Toshihiro
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2024-10-02
- Volume
- 28
- Issue
- 10
- Pages
- 895-909
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W4403616184
- Semantic Scholar
- 86bc68d7ffe52e524f453f903d2fb70d1b7f97e0
- Cited by
- 27
- References
- 99
- Citations by year
- 2026: 14 · 2025: 12 · 2024: 1
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Therapeutic Targets (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AMED (JP24ck0106741)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- glypican-3, hepatocellular carcinoma, cancer immunotherapy, peptide vaccine, mRNA vaccines, antibody therapy, CAR T-cell therapy, T cell receptor T cell therapy, immune checkpoint inhibitors, adjuvant therapy, tumor recurrence prevention, heparan sulfate proteoglycans, reverse translation
- MeSH terms
- Animals, Antigens, Neoplasm, Carcinoma, Hepatocellular, Humans, Immunotherapy, Liver Neoplasms, Cancer Vaccines, Glypicans, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
